ACADIA Pharmaceuticals Inc. (ACAD) Stock Overview
Explore ACADIA Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
ACADIA Pharmaceuticals Inc. (ACAD)
Key Financials
Key Financials
Market Cap
5.1B
P/E Ratio
13.04
EPS (TTM)
$2.22
ROE
0.32%
ACAD Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, ACADIA Pharmaceuticals Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ACAD on the NASDAQ shows an RSI of 62.77, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $27.14 for the NASDAQ listing.
Key metrics behind ACADIA Pharmaceuticals Inc.'s NASDAQ-traded stock include a P/E ratio of 13.04 and a market capitalization of 5.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ACAD on the NASDAQ.